Starting and Maintaining Patients on Biologics and Janus Kinase Inhibitors for Various Immune-mediated Inflammatory Dermatologic Conditions

Targeted therapies, including biologics and small molecules like Janus kinase inhibitors, have revolutionized the treatment of challenging immune-mediated inflammatory skin conditions. However, their use in the Philippines remains limited, primarily due to economic barriers. In this article, we address the key challenges faced in initiating and sustaining patients on these therapies.